Premium
Serum levels of the IgA isotype switch factor TGF‐β1 are elevated in patients with COVID‐19
Author(s) -
Wang Eryi,
Chen Hao,
Sun Baoqing,
Wang Hui,
Qu HuiQi,
Liu Yichuan,
Sun Xizhuo,
Qu Jingchun,
Fang Zhangfu,
Tian Lifeng,
Zeng Yifeng,
Huang ShauKu,
Hakonarson Hakon,
Liu Zhigang
Publication year - 2021
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.14104
Subject(s) - isotype , covid-19 , immunoglobulin class switching , immunology , transforming growth factor , antibody , immune system , immunoglobulin a , activator (genetics) , biology , immunoglobulin g , medicine , virology , monoclonal antibody , disease , genetics , gene , infectious disease (medical specialty) , endocrinology , b cell , outbreak
We previously observed enhanced immunoglobulin A (IgA) responses in severe COVID‐19, which might confer damaging effects. Given the important role of IgA in immune and inflammatory responses, the aim of this study was to investigate the dynamic response of the IgA isotype switch factor TGF‐β1 in COVID‐19 patients. We observed, in a total of 153 COVID‐19 patients, that the serum levels of TGF‐β1 were increased significantly at the early and middle stages of COVID‐19, and correlated with the levels of SARS‐CoV‐2‐specific IgA, as well as with the APACHE II score in patients with severe disease. In view of the genetic association of the TGF‐β1 activator THBS3 with severe COVID‐19 identified by the COVID‐19 Host Genetics Initiative, this study suggests TGF‐β1 may play a key role in COVID‐19.